FLGT News and Press, Fulgent Genetics Inc. From 12/01/22

SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fulgent Genetics, Inc. (NASDAQ: FLGT). Investors who purchased Fulgent Genetics, Inc. (NASDAQ: FLGT) shares long-term and continue to hold any ...

Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. Since the end of 2019, its shares are up 187% compared to the S&P 500 's 23%. While that's an impressive market beat, there was a point in early 2021 when Fulgent's stock was up ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced...

Summary Bull says deep valued 1x EV/S (core biz), getting its Covid biz for free. Bear says self-dealing, disregard of shareholder interests, and zero corporate governance left. I present both cases and my (painful) reflection. Bull Case As many SA authors covere...

The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Fulgent Genetics, Inc. 2022 Q3 - Results - Earnings Call Presentation

Fulgent Genetics, Inc. (FLGT) Q3 2022 Results Conference Call November 07, 2022 04:30 PM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Paul Kim - CFO Brandon Perthuis - Chief Commercial Officer Dr. Ray Yin - President and Chief Scientific ...

Fulgent Genetics ( NASDAQ: FLGT ) said Monday it acquired Fulgent Pharma , an independent clinical-stage pharmaceutical firm, for ~$100M. The deal amount will be paid with cash on hand and Fulgent Genetics' ( FLGT ) stock. The combined firm plans to offer a ve...

Fulgent Genetics press release ( NASDAQ: FLGT ): Q3 GAAP EPS of $0.06. Revenue of $105.66M (-53.6% Y/Y). Core Revenue grows 110% year-over-year to $56.0 million Billable tests delivered 952,000, versus 2.2 million in Q3 2021 Adjusted EBITDA of $19.7 million ...

Fulgent Genetics aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology Fulgent Pharma’s proprietary novel nano-drug delivery technology platform synergistically underpins the combined busi...

Revenue totals $105.7 million Core Revenue grows 110% year-over-year to $56.0 million Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused...